Kristi Rosa

Neoadjuvant gemcitabine plus cetrelimab shows promising pCR and RFS rates in muscle-invasive bladder cancer, highlighting new treatment options.

New findings reveal that perioperative enfortumab vedotin and pembrolizumab significantly enhance survival rates in muscle-invasive bladder cancer patients.

Datopotamab deruxtecan significantly enhances survival rates in first-line treatment for metastatic triple-negative breast cancer, offering new hope for patients.

New findings reveal I-DXd's promising efficacy in treating extensive-stage small cell lung cancer with brain metastases, showcasing significant response rates.

Combining local consolidative therapy with osimertinib enhances progression-free survival in metastatic EGFR-mutant non-small cell lung cancer patients.

Tarlatamab-dlle combined with anti-PD-L1 therapy shows remarkable survival rates and manageable safety in extensive-stage small cell lung cancer patients.

SHR-4849 shows promising efficacy and manageable safety in relapsed small cell lung cancer, highlighting its potential as a targeted treatment option.

Ifinatamab deruxtecan shows promising antitumor activity in extensive-stage small cell lung cancer, with high response rates and durable outcomes.

Osimertinib combined with chemotherapy significantly enhances overall survival in advanced EGFR-mutated non-small cell lung cancer, according to FLAURA2 trial results.

Atezolizumab and bevacizumab enhance TACE effectiveness, significantly extending progression-free survival in unresectable HCC patients, as shown in the TALENTACE trial.

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell lung cancer.

Combination therapy of osimertinib and datopotamab deruxtecan shows promising efficacy in advanced NSCLC, warranting further phase 3 studies.

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation due to adverse effects significantly.

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard treatments in recent trials.

The IRAKLIA study reveals that subcutaneous isatuximab offers comparable efficacy and improved patient satisfaction over intravenous administration for multiple myeloma.

Neoadjuvant nivolumab plus chemotherapy significantly improves overall survival in resectable non-small cell lung cancer, marking a treatment breakthrough.

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in high-risk locally advanced cervical cancer, establishing a new standard of care.

Dose adjustments enabled longer NALIRIFOX exposure and survival in select metastatic PDAC patients, with favorable clinical profiles despite multiple metastatic sites.

Sacituzumab govitecan & pembrolizumab significantly improved PFS in PD-L1+ advanced TNBC vs. chemo/pembrolizumab in the ASCENT-04 study.

Lurbinectedin plus atezolizumab maintenance significantly improved PFS & OS in extensive-stage SCLC, offering a potential new standard of care.

ENVISION trial 18-month data show UGN-102 yielded a high initial complete response (79.6%) in recurrent low-grade intermediate-risk NMIBC, with 80.6% maintaining response. The gel formulation with mitomycin offers a nonsurgical chemoablation with favorable tolerability.

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after suboptimal first-line therapy.

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in lenalidomide-refractory multiple myeloma.

Enfortumab vedotin plus pembrolizumab doubled progression-free survival vs chemotherapy in urothelial cancer.

Trifluridine/tipiracil improved DFS in stage IV CRC with molecular residual disease but not in the full ALTAIR study population.

Balstilimab plus botensilimab improved ORR over botensilimab alone in MSS mCRC without liver metastases, per phase 2 data.

The combination of pelareorep and modified FOLFIRINOX with or without atezolizumab had an acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.

Data presented at ASH 2024 showed that tafasitamab led to a progression-free survival of 11.3 months and an overall survival of 24.8 months in patients with relapsed/refractory DLBCL.

Treatment with anitocabtagene autoleucel produced durable efficacy in patients with relapsed/refractory multiple myeloma.